Figure 3.
Novel targeted therapies in development for acute myeloid leukemia (AML). The figure shows the novel targeted therapies discussed in this review that are in development for treating AML. These include menin inhibitors, tumor suppressor agents, MCL-1 inhibitors, and XPO1 inhibitors that have recently been used for other hematologic malignancies, but have not been approved for AML. Abbreviations: MCL-1: myeloid cell leukemia 1; XPO1: exportin-1.